My alert for NUMI's daily 12 EMA went off 12/21/2020 and have a tiny entry there. Wanted to add more to the 26 EMA (left) but missed it and it's seeing a solid 10-12% bounce from that. Hourly chart (right) looks like it could be setting up an hourly bear flag which has me cautious here. My position is very tiny; if doing swing trades on penny stocks I think it's...
I've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82: However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a...
Abbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume...
AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15...
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic,...
Long term target 125 Roadmap: 2,8 - 12 - 1,5 - 125
Biotech situated for nice influx of capital worldwide.
Johnson § Johnson is one of the companies working on coronavirus treatments§vaccines. They need to develop one otherwise as technically monthly looks very ugly
We just checked pharmacies around the North East PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States. Its parent company ranks as the 7th largest U.S. corporation by...
Just my prediction on ACB. Looks like it's going up. Could keep climbing until around the time of the earnings report. Earnings report on September 9/23.
NVCR - Novocure - oversold on the weekly and oversold on the daily. Could setup for a nice bounce back here!
Hello all, We bounced off of the line as I suspected might happen. I am expecting TLRY to at least retest the $180 dollar region if not make new all time highs. I would not put it past the market. Would not recommend a short right now, confirmation is needed. Good luck. -YoungShkreli
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...
AbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B. Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions...
Not sure if the BLUE support is gonna hold this time around. Might eventually sets on ~9yr-old support (note chart is in Log scale). Monthly chart also showing massive MACD divergence. As a result, sold my position to see how is gonna play out in the ST. Also binary outcome drug data expected this year, with unknown timing. However, INCY is top pick at Credit...
This is my first wave chart, so be gentle. :) i have 2 scenario. One is that wave 5 have ended and we are ready to a correctional wave of A,B,C. The other is that they will present bad revenue. And the price will continue the down trend, and stop at the support line at 6,49 where the 5th wave could end and start a correction of A,B,C. Fundamental: Teva have a...
The wave 2 correction in Mangalam Drugs seems to have become a bit complex. Now it appears to be at a structural support. Also there is 61% Fib support. So it's likely that the up move could start. Any move below wave 1 low would negate this setup.